Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | BCL6 | P41182 | 1/20 | 0.43 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22191340 | 0.91 | PDE3B (0.48) | KDM4CKDM4EKDM6BKDM4AKDM4D | |
| SCHEMBL22191095 | 0.76 | PLK4 (0.50) | PDE3BPDE3AGSK3BCLK4MAP4K4 | |
| SCHEMBL22191227 | 0.76 | PDE3B (0.47) | KDM4EPDE3BPDE3AGSK3BCLK4 | |
| SCHEMBL22191404 | 0.75 | MAP4K4 (0.47) | PDE3BPDE3AGSK3BCLK4CDC7 | |
| SCHEMBL22190852 | 0.74 | RAB9A (0.46) | GSK3BCLK4CDC7MAP4K4MKNK2 | |
| SCHEMBL22191260 | 0.74 | KMT2A (0.45) | KDM4EGSK3BCLK4MAP4K4MKNK2 | |
| SCHEMBL22191334 | 0.74 | PLK4 (0.48) | KDM4EPDE3BPDE3AGSK3BCLK4 | |
| SCHEMBL22191355 | 0.74 | FYN (0.60) | PDE3BPDE3AGSK3BCLK4ROCK2 | |
| SCHEMBL22191347 | 0.73 | PDE3B (0.60) | KDM4EPDE3BPDE3AGSK3BCLK4 | |
| SCHEMBL22191614 | 0.72 | DYRK1A (0.54) | CLK4CDC7DYRK1ACLK2DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3906233-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-31 | — | — | EP | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| EP-3906233-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-113508111-A | Kinase inhibitor compounds and compositions and methods of use | 西奈山伊坎医学院 | 2021-10-15 | — | — | CN | disclosed |
| WO-2020142485-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | MAP3K20, MAP3K1, PACSIN2 | KDM4C 2597/4885KDM4E 2309/4885KDM6B 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.